Are peptides safe? It depends on which of three kinds you mean

Whether a peptide is safe depends almost entirely on which of three routes it came by. FDA-approved peptide drugs have their risks measured in large trials and printed on the label. Compounded peptides are made by pharmacies without FDA review of the product. Products sold “for research use only” have no safety review of any kind. Start with what peptides are if the groups are new to you, or the wider peptide basics. The FDA status tracker says which group each peptide falls into.

Are FDA-approved peptides safe?

They are safe enough that FDA judged the benefits to outweigh the risks for a specific use, which is a different thing from risk-free. Approval means the risks were measured in controlled trials, weighed against the benefit, and written down. The label, also called the prescribing information, is where they live. It lists contraindications (people who must not take the drug), warnings and precautions, and the adverse reactions seen in trials with their rates.

A boxed warning is the strongest warning FDA requires, printed in a black box at the top of the label. Among peptide drugs, the best known is on the GLP-1 class.

The thyroid warning shows how labels work. In rats and mice, GLP-1 drugs caused thyroid C-cell tumors. Whether that happens in people is not known, so the label does two things: it bars the drug for people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2), an inherited cancer syndrome, and it tells prescribers to counsel every patient about neck lumps, trouble swallowing and persistent hoarseness.

Bremelanotide shows the other end. Its label has no boxed warning, but nausea was the most common reaction in the phase 3 trials: 40% of patients had it, 13% needed anti-nausea medicine, and 8% dropped out because of it.

Are compounded peptides safe?

They carry more risk than the approved drug because nobody outside the pharmacy checks the finished product. FDA puts it plainly: “Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.” A compounded semaglutide or tirzepatide contains the same molecule as the approved drug, so the label’s drug risks still apply. What compounding adds are the risks of the product itself.

Adverse event reports

As of May 31, 2026, FDA had received 990 adverse event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide, and says these are “likely” underreported, because state-licensed pharmacies that are not outsourcing facilities do not have to report them. Some reports involved hospitalization. A report is not proof the drug caused the event, but the numbers are why FDA keeps a standing page on the problem.

Dosing errors

Approved GLP-1 pens deliver a fixed dose with a click. Compounded versions usually come as a multi-dose vial, drawn up with an insulin syringe measured in units, while the prescription is written in milligrams. That is three units of measure for one dose. FDA has received reports of patients measuring the wrong dose and of clinicians miscalculating it. A poison control center case series described two patients who injected ten times their intended dose of compounded semaglutide; all three patients in the series had days of nausea, vomiting and abdominal pain, and one patient reported dosing “in milliliters and units rather than in milligrams.” The mg to units converter shows how the conversion works; the pharmacy label and the prescriber set the dose.

Ingredient quality

A licensed pharmacy is only as good as its ingredients. In August 2026, FDA reported at least 30 patients with fever, chills, shock and sepsis-like symptoms after intravenous glutathione compounded from a dietary-supplement-grade ingredient. The symptoms were consistent with endotoxin, a toxic fragment of bacterial cell walls, and some patients were hospitalized. Glutathione is a tripeptide rather than one of the peptide drugs this site profiles, but the lesson carries to any compounded injectable: FDA said supplement-grade ingredients are “not an appropriate ingredient to make injectable drugs” and that testing alone does not ensure quality.

Did the October 2026 HHS policy make six peptides safe?

No. As of November 2, 2026, an interim HHS policy says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding BPC-157, TB-500, MOTS-c, epitalon, KPV or semax, when ten conditions are met, until a final rule decides each one. That is a decision about enforcement. It is not evidence that any of the six works or is safe, and none of them is FDA-approved.

Some of the conditions do address product quality. The bulk ingredient has to come from an FDA-registered maker with a certificate of analysis, each product may hold only one active ingredient, and serious adverse events have to be reported to FDA MedWatch. HHS may revisit the policy if a safety signal or quality problem appears. What the conditions cannot supply is the missing human data. FDA’s drug center recommended against listing all six, and the wording on its safety page, quoted below for BPC-157, has not changed.

Are research-use-only peptides safe?

This is where the safety question has no reassuring answer. Under 21 CFR 312.160, a “research use only” drug may be shipped only for tests in laboratory animals or in vitro, labeled not for use in humans. It is not legal to use on people, and FDA warning letters, including five sent to online peptide sellers on August 24, 2026, have found that the disclaimer does not change what a product is when the seller’s website offers dosing guidance and reconstitution calculators. HHS’s own policy describes “research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients.”

No human safety data

For most of these molecules, the safety question has never been studied in people. FDA’s review of BPC-157 for compounding found the agency “lacks sufficient information to know whether the drug would cause harm when administered to humans.” Similar language covers several other popular peptides on the same FDA page. The peptides A to Z states the evidence level for each one.

What lab tests of these products found

Independent tests have repeatedly found that what is in the vial is not what is on the label.

Endotoxin matters because it is not removed by the bacteriostatic water added to a vial, and it survives when the bacteria themselves are dead. A product can pass a sterility test and still carry enough endotoxin to cause fever and shock. The guide to reading a COA explains the tests that are supposed to catch this and why a seller’s certificate is not a substitute for them.

Emergency visits

The clearest population data so far comes from Australia. New South Wales Health searched emergency department triage notes for mentions of unapproved peptides and found 1,180 presentations between July 1, 2025 and September 30, 2026, rising from 5 in July 2025 to 217 in September 2026. Most mentioned retatrutide, an investigational drug that is not approved in Australia or the United States.

The most common diagnoses were gastrointestinal (abdominal pain, nausea, vomiting), cardiovascular (including chest pain), and allergic reactions including anaphylaxis. 18% of the visits led to hospital admission, and a quarter of patients were 16 to 24. NSW Health also reported kidney damage and liver injury through its Poisons Information Centre. Its report notes that keyword searches likely miss cases, so the true number is probably higher.

What is immunogenicity, and why does FDA keep mentioning it?

Immunogenicity is a product’s tendency to provoke an immune response, in which the body treats the drug as a foreign invader. It comes up again and again on FDA’s page of bulk substances with safety concerns. FDA uses nearly the same sentence for BPC-157, TB-500, semax, epitalon, selank, ipamorelin, CJC-1295, thymosin alpha-1 and others: the compounded drug “may pose risk for immunogenicity for certain routes of administration,” often because of aggregation (molecules clumping together) or peptide-related impurities (fragments and near-copies left over from manufacturing).

This is a risk that a purity number on a label does not settle. It depends on the molecule, how it was made, how it was stored and how it enters the body. FDA also flags that for several of these peptides it has little or no human data to judge the size of the problem, and it rates the risk as “significant” for some, including AOD-9604, MOTS-c and thymosin alpha-1.

Do peptides cause cancer?

There is no single answer, and for most unapproved peptides the question has not been studied in people. What exists is specific to each drug:

Case reports and animal findings do not prove a cause. They are also the most anyone has for many of these molecules, which is a different thing from reassurance.

How to judge any safety claim about a peptide

Ask which rung of the evidence ladder the claim stands on. “Natural” is no help, because the body makes peptides such as insulin and they can still do serious harm at the wrong dose. “No side effects reported” is no help either if nobody was watching. A study in rodents can be a good reason to run a human trial, and it tells you very little about what an injection will do to you.

What to watch for

• Approved drug: read the label’s contraindications before the first dose. For GLP-1 drugs, the label lists severe abdominal pain that does not go away (possible pancreatitis) and a lump or swelling in the neck as reasons to contact a prescriber.
• Compounded drug: confirm the dose in milligrams and in syringe units with the pharmacist before the first injection, and check the pharmacy label for a patient name, strength and beyond-use date. The compounded tirzepatide guide covers the label.
• Research product: there is no safe version. NSW Health’s advice to anyone already using one is to speak with a health professional before taking another dose, and to tell any treating clinician about it, especially before surgery.

Any suspected reaction to a drug in the United States can be reported to FDA MedWatch at 1-800-FDA-1088. Severe symptoms such as trouble breathing, fainting or chest pain are an emergency.